Virtuvax to attend DCVMN in Kunming
- Ernst Soethout, MD
- 19 sep 2018
- 1 minuten om te lezen
Virtuvax consults in vaccine development and provides biosimilar and vaccine technologies. A most recent one, is the prefusion RSV-F vaccine technology. If you are interested, I would be most interested to meet you at the developing countries vaccine manufacturers network (DCVMN) annual meeting in Kunming, China, from October 29 - 31 2018.
Tags: vaccine development, disruptive technology, biosimilar, monoclonal antibody, vaccine technology, DCVMN, Kunming, vaccine consultancy, RSV, pre-fusion RSV-F, RSV vaccine, pneumococcal vaccine
Recente blogposts
Alles weergevenPatented technology applied in SynGEM, a needle-free nasal spray vaccine against respiratory syncytial virus * Re-Issuance of U.S. Patent...
SynGEM a needle-free nasal spray vaccine against respiratory syncytial virus * SynGEM shown to be safe and immunogenic in healthy adults...
